Clinical Trials Update: June 30, 2009

July 1 -- (HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch and ClinicalConnection.com:

Chronic Obstructive Pulmonary Disease (COPD)

If you are at least 40 and a current or former smoker with chronic obstructive pulmonary disease, chronic bronchitis or emphysema, you may qualify for this study.

The research site is in St. Louis, Mo.

More information

Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=44.

-----

Glioblastoma multiforme

If you are an adult with newly diagnosed, unilateral glioblastoma multiforme (grade IV), you may be eligible for this study.

The research site is in Morristown, N.J.

More information

Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=685.

-----

Fibromyalgia

If you are an adult with fibromyalgia, you may qualify for this study.

The research site is in Lexington, Ky.

More information

Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=218.

-----

Type 2 Diabetes

This study will evaluate the effectiveness of an investigational drug in people with type 2 diabetes mellitus.

The research site is in San Antonio, Texas.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/diabetes.aspx.

-----

Depression (Ages 18+)

This study will evaluate the safety and effectiveness of an investigational drug taken by men and women with major depressive disorder.

The research site is in Upland, Calif.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/depression.aspx.

-----

Depression

This study is for people diagnosed with depression. Qualified participants will receive study related health assessments and study medication at no cost, and compensation for time and travel.

The research sites are located nationwide.

More information

Please see http://www.clinicalconnection.com/5666.aspx.

-----

Copyright 2009 CenterWatch and ClinicalConnection.com. All rights reserved.